. 2016 Jul 12;17(1):180–190. doi: 10.1111/ajt.13886

Table 2.

Cumulative incidence rates of selected adverse events adjusted per 100 person‐years of treatment exposure

Cohort	Serious infection^a	Any‐grade viral infection^b	Any‐grade fungal infection^b	Any‐grade malignancy^a
UNOS ECD
Belatacept MI	22.56	22.65	10.84	4.46
Belatacept LI	18.06	16.26	6.46	3.77
CsA	23.48	22.57	11.06	4.46
DCD
Belatacept MI	19.81	19.34	9.81	3.78
Belatacept LI	13.37	12.64	6.50	1.99
CsA	24.79	18.76	8.12	4.86
Anticipated CIT ≥24 h
Belatacept MI	24.21	17.60	7.20	2.02
Belatacept LI	14.30	25.09	8.71	2.26
CsA	12.47	11.95	11.99	1.06

CIT, cold ischemia time; CsA, cyclosporine; DCD, donation after cardiac death; ECD, expanded criteria donor; LI, less intensive; MI, more intensive; UNOS, United Network for Organ Sharing.

The duration (patient‐years) of patient exposure to assigned study drug was calculated from the randomization date to the event date, to the date of last follow‐up or to month 84, whichever was earliest.

The duration (patient‐years) of patient exposure to assigned study drug was calculated from the randomization date to the event date, to the date of last dose of study medication plus 56 days or to month 84, whichever was earliest.